Skip to main content
PMC home page
Frontiers in Neuroscience logoLink to Frontiers in Neuroscience
. 2022 Mar 11;16:828382. doi: 10.3389/fnins.2022.828382

Integrated Metabolomics and Proteomics Analysis of Urine in a Mouse Model of Posttraumatic Stress Disorder

Daxue Zhou 1, Chengyan Long 2, Yan Shao 1, Fei Li 1, Wei Sun 1, Zihan Zheng 1, Xiaoyang Wang 1, Yiwei Huang 1, Feng Pan 1, Gang Chen 1,3,4,*, Yanlei Guo 2,*, Yi Huang 1,*
PMCID: PMC8963102  PMID: 35360173

Abstract

Posttraumatic stress disorder (PTSD) is a serious stress disorder that occurs in individuals who have experienced major traumatic events. The underlying pathological mechanisms of PTSD are complex, and the related predisposing factors are still not fully understood. In this study, label-free quantitative proteomics and untargeted metabolomics were used to comprehensively characterize changes in a PTSD mice model. Differential expression analysis showed that 12 metabolites and 27 proteins were significantly differentially expressed between the two groups. Bioinformatics analysis revealed that the differentiated proteins were mostly enriched in: small molecule binding, transporter activity, extracellular region, extracellular space, endopeptidase activity, zymogen activation, hydrolase activity, proteolysis, peptidase activity, sodium channel regulator activity. The differentially expressed metabolites were mainly enriched in Pyrimidine metabolism, D-Glutamine and D-glutamate metabolism, Alanine, aspartate and glutamate metabolism, Arginine biosynthesis, Glutathione metabolism, Arginine, and proline metabolism. These results expand the existing understanding of the molecular basis of the pathogenesis and progression of PTSD, and also suggest a new direction for potential therapeutic targets of PTSD. Therefore, the combination of urine proteomics and metabolomics explores a new approach for the study of the underlying pathological mechanisms of PTSD.

Keywords: posttraumatic stress disorder (PTSD), PTSD model, urine, metabolomics, proteomics, mice

Introduction

Post-Traumatic Stress Disorder (PTSD) is a persistent stress disorder type that may be delayed or imminent following major psychological trauma (Kessler et al., 1995; Breslau et al., 1998). PTSD can be caused by a variety of major events, including diseases (Kangas et al., 2005; Bush, 2010), war incidents (Owens et al., 2005), natural disasters (Wu et al., 2009), etc. PTSD has four core symptoms according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5); the re-experiencing of traumatic event(s), continuous avoidance of trauma-related stimuli, negative emotions related to cognitive trauma, and continued increase in alertness (Mahan and Ressler, 2012; Tandon, 2014; Tanaka et al., 2019). Several of these aspects can be captured using situational reminder programming in animal models, leading it to become a common model for studying the symptoms and mechanisms of PTSD. However, the precise molecular changes occurring in these models remains incompletely understood.

Assessments for compositional changes in urine have been demonstrated to have considerable potential for monitoring bodily health (Gao, 2013; Nicholas, 2020). In comparison with blood, urine has the advantages of being non-invasive, convenient to sample repeatedly, biochemical stability, and so on (Wu and Gao, 2015; Jing and Gao, 2018). In addition, urine may not be as strongly regulated by homeostatic mechanisms (Wang et al., 2014; Huang and Lo, 2018). The detection of blood biomarkers usually reflects the relatively stable state in the middle and late stages of the disease (Li, 2015), but misses the signals of short-term changes in the early stage of the disease. In opposite urine, as a blood filter, will collect all the body’s metabolites, thereby detecting more differentiated factors (Li et al., 2014; Gao, 2015). Moreover, recent reports have shown that urine can provide a lot of non-urogenital information, including regarding neuropsychiatric disorders (Emanuele et al., 2010; Marc et al., 2011).

In the past few years, advances in “omics” technology have yielded powerful new tools for biomarker screening, disease mechanism identification, and diagnostic modeling (Petricoin et al., 2006). Cutting-edge “omics” technology has already been deployed to study PTSD. Diverse epigenetic phenomena have enabled researchers to discover conserved molecular mechanisms involved in chromatin modification (Goldberg et al., 2007), especially non-coding RNAs, which play an important role in multiple epigenetic phenomena (Bernstein and Allis, 2005). Studies on PTSD and miRNA have revealed several key contributors to the underlying pathophysiological basis of PTSD (Wingo et al., 2015; Bam et al., 2016a,b; Martin et al., 2017). Genomics research can be used to analyze DNA and RNA sequences by second-generation sequencing and third-generation sequencing techniques to discover new transcripts or exon single nucleotide polymorphisms (SNPS) (Girgenti and Duman, 2018). However, researchers thus far have primarily used blood and postmortem brain tissue to identify biomarkers for PTSD (Thomson et al., 2014; Breen et al., 2015; Bharadwaj et al., 2018). Glycomics studies can analyze the biological functions of all glycans by studying the unique pond group of organisms (Miura and Endo, 2016). Compared with genome sequence discovery, glycomics can better reflect the biological state of complex diseases (Zoldos et al., 2013; Lauc et al., 2016). It has been reported that there are significant changes in the N-glycomic group in psychiatric and neurodegenerative diseases (Vanhooren et al., 2010; Lundstrom et al., 2014; Park et al., 2018). Proteomics studies the complete set of proteins in a biological system (cell, tissue or organism) in a given state at a given time, analyzing changes in protein expression, post-translational modifications, and protein-protein interactions (Wilkins et al., 1996; Jensen, 2006). It is more complex than genomics, but can reflect the precise functional characteristics of proteins (Baloyianni and Tsangaris, 2009). Metabolomics mainly analyses final or intermediate small molecule metabolites produced by gene regulation and can evaluate metabolites altered by treatment or disease (Kaddurah-Daouk and Krishnan, 2009; Mastrangelo et al., 2016). It is reported that metabolomics plays an important role in analyzing the metabolic profile, inflammatory mechanisms and biomarker identification of PTSD (De Bellis et al., 2000; Pace and Heim, 2011; Karabatsiakis et al., 2015; Bersani et al., 2016; de Vries et al., 2016; Hemmings et al., 2017; Mellon et al., 2018; Nedic Erjavec et al., 2018). Therefore, Omics technologies can be further improved study the underlined mechanisms of PTSD and identify diagnostic and prognostic biosignatures.

Despite the promising features of urine biomarkers, the biological interpretation of single typology data is very challenging due to the complexity of urine samples. Therefore, in this study, the analytical capabilities of proteomics and metabolomics were combined to obtain more comprehensive data on mice in the normal group and PTSD group, aiming to discover new potential biomarkers.

Materials and Methods

Induction of Electric Foot Shock Stress

Twelve healthy male 8–10 weeks old C57BL/6 mice were purchased from Laboratory Animal Centre at the Army Medical University. All mice were housed in individual cages under a reversed 12 h light/12 h dark cycle (light on at 6 AM) and standard laboratory conditions (21 ± 1°C, 55 ± 5% relative humidity). Food and water were provided ad libitum. This study was approved by the Ethics Committee of Army Medical University (Animal Ethics Statement: AMUWEC20211605). As shown in Figure 1, after a 14-day adaptation phase, the mice were divided into plantar foot shock group (PTSD group, n = 6) and non-foot shock group (control group, n = 6). Mice were subjected to electric foot shock in a Plexiglas chamber (27 × 20 × 300 cm3) with a grid floor made of stainless-steel rods (0.3 cm diameter, spaced 1.0 cm apart) connected to a shock generator. After a habituation period of 2 min, the mice in the foot shock group received a series of foot shocks of medium (0.15 mA) intensity of 10 s duration with foot shock interval of 10 s being delivered for 5 min to produce acute stress (Rabasa et al., 2011). The mice in the control group were placed in the chamber for a similar period without receiving a foot shock. Thereafter, the mice in the foot shock group were subjected to the same moderate electric foot shock stressor for 12 days (twice a day) to induce stress adaptation (Van den Berg et al., 1998; Daniels et al., 2008).

FIGURE 1.

FIGURE 1

Open in a new tab

The experimental procedure for PTSD. EPM, elevated plus maze; OFT, open field test.

Behavioral Test

All the behavioral tests were performed in daytime from 8 AM to 3 PM. Mice were given two tests a day to avoid the potential interference from the other tests. Animal cages were moved to a testing room at least 0.5 h before each test. After completion of the test session, the behavioral apparatus and chamber were cleaned with 70% ethanol and then completely hand-fan dried.

Elevated Plus Maze Test

The apparatus consisted of four arms (28 cm × 5.8 cm width), with two arms open and two closed by gray walls (15.5 cm height) arranged on the opposite side of the same type. The platform was located 55 cm above the floor of the testing room illuminated and four arms were connected in the center platform (5 cm × 5 cm), where the animal was placed facing a closed arm. The position and movement of the animal were monitored for 5 min by a video camera. An entry was defined as more than half of the animal’s full body entering the open arm. The time spent in the open arms and the number of visits to the open arms were analyzed.

Open Field Test

The periphery and bottom of the test space were made of black opaque metal sheets, with length 72 cm, width 72 cm, and height 60 cm. The floor area was divided into 16 squares of the same size. During the test, each mouse was placed in the center of the area and was allowed to freely explore the area for 5 min. The numbers of crossing and standing were recorded during the last 4 min by technicians. After each test, the open area was washed with 70% ethanol to avoid any olfactory cues.

Urine Sample Collection

Urine was collected on ice using metabolic cages at the end of the experiment from 9:00 pm to 9:00 am in the next day. The collected urine was centrifuged at 13,000 g for 20 min at 4°C to obtain the supernatant sample. The average sample size was 2 mL. The urine sample was stored at −80°C before analysis.

Metabolomics Analysis

Urine samples (50 μL) were thawed on ice and immediately mixed with 200 μL of ice-cold acetonitrile. After mixing by vortex for 1 min, the mixture was centrifuged at 13,000 g for 15 min at 4°C. A supernatant aliquot of 10 μL was used for liquid chromatography-mass spectrometry (LC-MS/MS) analysis. Quality control (QC) samples were prepared by supernatant aliquot with an equal amount (15 μL) and were periodically analyzed throughout the complete run to monitor signal drift.

The LC 30A UHPLC system (Shimadzu, Kyoto, Japan) was linked to a Triple TOF 4600 system (SCIEX, Framingham, MA, United States). The separation step was conducted using the hydrophilic interaction liquid chromatography (HILIC) and the reversed-phase liquid chromatography (RPLC) methods. A Kinetex C18 column (2.1 mm × 100 mm, 2.6 μm, 100 Å, Phenomenex) was used with a binary gradient method. Solvent A was 0.1% formic acid in water (vol/vol), and solvent B was 0.1% formic acid in acetonitrile (vol/vol). A flow rate of 0.35 mL/min was used, and the injection volume was 2 μL. The gradient program used was 15% B at 0 min to 85% B at 10 min, with a total running time of 15 min. A TSK gel NH2-100 column (2.1 mm × 100 mm, 3.0 μm, TOSOH) was also used with a binary gradient method. Solvent A was 5 mmol/L ammonium acetate, and solvent B was acetonitrile. A flow rate of 0.25 mL/min was used, and the injection volume was 2 μL. The gradient program used was 100% B at 2 min to 15% B at 15 min, and at 20 min to 100% B, with a total running time of 25 min.

Proteomics Analysis

1 mL urine sample was thawed and transferred to a centrifuge tube, and then centrifuged at 12,000 g at 4°C for 30 min to remove impurities. The samples were six times mixed with the volume of acetone, fully mixed, and precipitated overnight at – 20°C. The mixture was removed and centrifuged at 12,000 g at 4°C for 30 min to remove the supernatant. The precipitate was dissolved in pyrolysis buffer solution (8 mol/L urea, 2 mol/L Thiourea, 50 mmol/L Tris, and 25 mmol/L DTT), and completely dissolved, centrifuged at 12,000 g for 30 min at 4°C, and then the supernatant was saved. Protein concentration was determined using the Bradford method. 100 ug protein was added to each sample in a 30 KDa filter (millipore, MRCF0R030), Urea buffer solution (UA, 8 mol/L, 0.1 mol/L Tris–HCl, pH 8.5), and 25 mmol/L NH4HCO3 solutions were in turn washed several times. Protein samples were reduced with 20 mmol/L dithiothreitol (DTT, Sigma) at 37°C for 1 h, followed by 50 mmol/L iodoacetamide (IAA, Sigma) in darkness for 30 min. Then, the samples were centrifuged at 18°C for 30 min at 14,000 g, washed with UA and NH4HCO3, with trypsin being added (enzyme protein ratio 1:50) and digested overnight at 37°C. The peptide mixture was desalted using a C18 column (Thermo, 84850), concentrated, dried in vacuum, and stored at −80°C.

AU3000 UHPLC system (Thermo Fisher Scientific, Waltham, MA, United States) was used to separate the peptides. Peptides were loaded onto an analytical column (Acclaim™ PepMap™ 100, 75 μm × 15 cm, C18, 3 μm, 100 Å, Thermo Fisher Scientific, Waltham, MA, United States) with a Trap Column (Acclaim™ PepMap™ 100, 75 μm × 2 cm, C18, 3 μm, 100 Å, Thermo Fisher Scientific, Waltham, MA, United States) and separated by reversed-phase chromatography (U3000nano, Thermo Fisher Scientific, Waltham, MA, United States) using a 106 min gradient. The gradient was composed of Solvent A (0.1% formic acid in water) and Solvent B (0.1% formic acid in 80% acetonitrile) elution gradient: 1% B for 13 min, 1–30% B in 70 min, 30–90% B in 10 min, 90% B for 2 min and 90–1% B in 1 min, 1% B for 10 min. The eluted peptides were analyzed using the Data Dependent Acquisition (DDA) method applying one full MS scan (350.00–1800.00 m/z) in the Orbitrap at a resolution of 60,000 M/ΔM, followed by consecutive MS/MS (profile) scans in the ion trap by product ion scans (relative CID energy 35) of the 16 most abundant ions in each survey scan. The product ion scans were acquired with a 2.0 unit isolation width and a normalized collision energy of 35 in an LTQ-Orbitrap Velos Pro MS spectrometer (Thermo Fisher Scientific, Waltham, MA, United States).

Statistical Analysis

Statistical analyses were performed using SPSS 20.0 software, values are expressed as mean ± standard deviation (X ± SD, n = 6 per group), the graphics were generated using GraphPad Prism 8.0.1 software. Metabolomics and Proteomics data analyses were performed in MetaboAnalyst 5.0 and Proteome Discover Daemon 2.5. The metabolite peaks of the urine samples were normalized, analyses performed using SIMCA-P 14.1 multivariate statistical analysis software. All variables were tested and found to be normally distributed, an independent-samples student’s t-test was used to compare differences between the two groups, and identify differentially expressed metabolites and proteins, and then we used Ingenuity Pathway Analysis to analyze the significantly altered canonical pathways and molecular interaction networks. A p-value threshold of 0.05 was used to infer statistically significant findings, and a more strict p-value threshold of 0.01 was used to infer highly statistically significant changes.

Results

The Results of the Behavioral Test

Elevated Plus Maze Test

Elevated plus maze test was deployed to explore the potential anxiety actions of the induction of electric foot shock stress. There was no significant difference in terms of total arms entries (Figure 2A) and total time spent in the arms (Figure 2B) between the control and the PTSD groups.

FIGURE 2.

FIGURE 2

Open in a new tab

The effect of the induction of electric foot shock on anxiety in the elevated plus-maze test in mice compared to the control group (n = 6). (A) Total arms entries; (B) Total time spent in the arms; (C) The percent of entries in open arms; (D) The percent of time spent in open arms; (E) The actual times spent in open arms; (F) The actual amount of entries in open arms. Results are provided in the form of mean ± SD. *p < 0.05; **p < 0.01.

The induction of the electric foot shock stress caused a significant reduction in the percent of open arm entries (open arm/total × 100) with the ones of the control and the PTSD group being 45.4 and 27.5%, respectively (Figure 2C). The percent of time spent in open arms was also significantly reduced when applying induction of electric foot shock stress with control and PTSD group values being 23.1 and 14.7%, respectively (Figure 2D). The actual times spent in open arms in the control group and the PTSD group were 578 s and 319 s, respectively (Figure 2E). The actual amount of entries in open arms in the control group and the PTSD group were 99 and 72, respectively (Figure 2F).

Open Field Test

The anxiety-like behavior of the induction of electric foot shock stress was measured with an open-field test. The overall distance was significantly reduced when applying induction of electric foot shock stress with the values of the control and PTSD groups being 1511.18 and 1292.94 cm, respectively (Figure 3A). The number of crossing and standing was also significantly reduced by the Induction of electric foot shock stress. The numbers of crossing in the control group and the PTSD group were 77.1 and 36.0 times, respectively (Figure 3B). The amount of times of standing in the control group and the PTSD group were 18.4 and 7.2 times, respectively (Figure 3C).

FIGURE 3.

FIGURE 3

Open in a new tab

The effect of the induction of electric foot shock on anxiety in the open-field test in mice compared to the control group (n = 6). (A) Overall distance; (B) Numbers of crossing; (C) Numbers of standing. Data are expressed as mean ± SD. **p < 0.01.

Metabolomics Analysis

Quality control results pinpointed that the variation caused by instrument error is small and the data quality is reliable (Supplementary Figure 1). The PCA results plot does not show clear segregation between the PTSD group and the control group (Supplementary Figure 2). In addition, The OPLS-DA model was established and a permutation test of the OPLS-DA model was performed (positive mode: R2X = 0.919, R2Y = 1.0, Q2 = 0.723; negative mode: R2X = 0.854, R2Y = 0.998, Q2 = 0.657; Figures 4A,B). The results of the permutation test showed the absence of overfitting (positive mode: R2 = 0.999, Q2 = −0.0431; negative mode: R2 = 0.995, Q2 = −0.0933; Figures 4C,D). In conclusion, the model presented good reliability and predictability.

FIGURE 4.

FIGURE 4

Open in a new tab

OPLS-DA score results and OPLS-DA quality control figure of mice urine samples. (A) Positive ion mode OPLS-DA scores; (B) Negative ion mode OPLS-DA scores; (C) Positive ion mode OPLS-DA permutation test; (D) Negative ion mode OPLS-DA permutation test; intercepts: R2 and Q2 represent y-intercept of R2 and Q2 regression lines.

Differential Metabolites

Metabolomics profiling of urine from the C57BL/6 normal group mice and the PTSD mouse-model group detected a total of 559 metabolite components and revealed 12 differentially expressed metabolites between the PTSD group and the Control group using as criteria to infer significant findings the VIP > 1 and p < 0.05 (Figure 5A and Table 1). These differentially expressed metabolites possess different characteristics (Figure 5B) and were enriched for several KEGG pathways associated with amino acid and nucleic acid metabolism, including Pyrimidine metabolism, D-Glutamine and D-glutamate metabolism, Alanine, aspartate and glutamate metabolism, Arginine biosynthesis, Glutathione metabolism, Arginine, and proline metabolism (Figure 5C).

FIGURE 5.

FIGURE 5

Open in a new tab

Metabolites profile shift during of mice urine samples between the PTSD group and the control group. (A) Volcano plot showing altered metabolites, Positive (up), negative (down) ion mode. The red dots indicate significantly upregulated metabolites (fold change > 1.2), while the green dots indicate significantly downregulated metabolites (fold change < 0.8). (B) Heat map of the differentially expressed metabolites. The red band indicates the upregulation of metabolites levels (fold change > 1.2), while the blue band indicates the downregulation of metabolites levels (fold change < 0.8). (C) KEGG pathway enrichment category of the differentially expressed metabolites, n = 6.

TABLE 1.

The significantly differentiated metabolites in control vs. post-traumatic stress disorder (PTSD) groups.

No Metabolites VIP FC P-value Trend
1 L-Methionine sulfone 1.27643 0.39592211 0.00128436 ↓
2 Docosanoic acid 1.11139 1.24292539 0.00153343 ↑
3 Uridine 2.21959 0.54969523 0.00295338 ↓
4 3-Hydroxyhippuric acid 1.10166 0.58905271 0.00886306 ↓
5 L-Glutamic acid 1.04933 0.42636368 0.00901154 ↓
6 Uridine 5′ monophosphate(UMP) 2.42806 0.47128583 0.02161141 ↓
7 Trans-2,3,4-Trimethoxycinnamic Acid 1.05031 0.46980814 0.02427128 ↓
8 β-D-Lactose 1.65882 0.51933915 0.02631537 ↓
9 Cytidine 3′-monophisphoric acid 3.48481 0.49014935 0.02692515 ↓
10 N-γ-Acetyl-N-2-Formyl-5-methoxykynurenamine 1.5343 0.52282757 0.02905089 ↓
11 Thymidine-5′-monophosphate(dTMP) 7.26583 0.50788472 0.03078474 ↓
12 Uridine-5′-diphosphate-mannose(UDP-Gal) 1.16583 0.49116102 0.03410945 ↓
Open in a new tab

Proteomics Analysis

The number of peptide-spectral matches, unique peptide number, and quantified proteins, were 88,734, 4,125, and 691 for both PTSD and control groups. 27 proteins exhibited significantly differentiated expression between the two groups using the criteria of p-value < 0.05 and fold change > 1.20 or <0.80. A total of 18 proteins among these were upregulated and 9 downregulated in the PTSD group compared to the Control group (Figure 6A and Table 2). These altered features were subjected to clustering, and the heat map revealed clusters with the ability to discriminate between control and PTSD samples (Figure 6B). Gene Ontology (GO) function annotation analysis showed that these differentially expressed proteins were mainly involved in biological processes, such as small molecule binding, transporter activity, extracellular region, extracellular space, endopeptidase activity, zymogen activation, hydrolase activity, proteolysis, peptidase activity and sodium channel regulator activity (Figure 6C). Based on the KEGG database, the significantly enriched pathways (P < 0.05) were Endocrine and other factor-regulated calcium reabsorption, Lysosome, Renin-angiotensin system, Carbohydrate digestion and absorption, Thyroid hormone synthesis, Metabolic pathways, Proximal tubule bicarbonate reclamation, Galactose metabolism and Starch and sucrose metabolism (Figure 6D).

FIGURE 6.

FIGURE 6

Open in a new tab

Proteomic profile shift of mice urine samples between the PTSD group and the control group. (A) Volcano plot showing dysregulated proteins. The red dots indicate significantly upregulated proteins (fold change > 1.2), while the green dots indicate significantly downregulated proteins (fold change < 0.8); (B) Heat map of the differentially expressed proteins. The red band indicates the upregulated proteins (fold change > 1.2), while the blue band indicates the downregulated proteins (fold change < 0.8); (C) Differentially expressed protein GO function enrichment diagram; (D) KEGG pathway enrichment of the differentially expressed proteins, n = 6.

TABLE 2.

The differentially expressed proteins in control vs. PTSD groups.

No UniProt accession Gene symbol Protein name FC P-value Trend
1 P49935 Ctsh Pro-cathepsin H −1.99023949 0.00163517 ↓
2 G5E861 Sclt1 Sodium channel and clathrin linker 1 2.07219424 0.00209911 ↑
3 A0A1L1SQP8 Fxyd2 FXYD domain-containing ion transport regulator 2.72899236 0.00222118 ↑
4 Q3TWT5 Asah1 Ceramidase 1.64659341 0.00282754 ↑
5 J3QK77 Scgb2b20 ABPBG20 3.07210788 0.00413095 ↑
6 Q9D1B1 Cst6 Cystatin E/M −3.19900397 0.00422517 ↓
7 A0A571BF69 Mgam Maltase-glucoamylase 2.37524214 0.00543735 ↑
8 Q4FZJ6 Wfdc2 WAP four-disulfide core domain 2 1.64128707 0.00604615 ↑
9 Q8K1H9 Obp2a Odorant-binding protein 2a 1.81533979 0.00799517 ↑
10 Q80YX8 Mup21 Major urinary protein 21 −2.29692495 0.00913460 ↓
11 Q3KQQ2 Mup3 Major urinary protein 25 −1.49751001 0.01240960 ↓
12 Q91WR8 Gpx6 Glutathione peroxidase 6 1.59143645 0.01390856 ↑
13 Q9D3H2 Obp1a Odorant-binding protein 1a −1.67221913 0.01499012 ↓
14 A2BHR2 Lcn11 Lipocalin 11 1.54440618 0.01672011 ↑
15 Q3TF14 Ahcy Adenosylhomocysteinase 1.82072680 0.01895520 ↑
16 A0A0U1RPF4 Hamp2 Hepcidin-2 (Fragment) 2.95442297 0.02102362 ↑
17 P10639 Txn Thioredoxin 1.993343846 0.027021861 ↑
18 A2CEK6 Mup13 Major urinary protein 11 −1.85239538 0.02745480 ↓
19 P15947 Klk1 Kallikrein-1 1.37162847 0.02874193 ↑
20 P70269 Ctse Cathepsin E 1.84456216 0.03194560 ↑
21 P51910 Apod Apolipoprotein D 1.69316293 0.03324157 ↑
22 P15948 Klk1b22 Kallikrein 1-related peptidase b22 1.73666194 0.03657697 ↑
23 H3BKH6 Esd S-formylglutathione hydrolase −1.63242181 0.03836365 ↓
24 L7MUC7 Mup7 Major urinary protein 7 (Fragment) −1.84000481 0.03930886 ↓
25 Q91XE4 Acy3 N-acyl-aromatic-L-amino acid amidohydrolase (carboxylate-forming) 2.79646484 0.04085258 ↑
26 Q91 × 17 Umod Uromodulin 1.56345644 0.04212900 ↑
27 B8JI96 Mup14 Major urinary protein 14 (Fragment) −1.54699463 0.04765555 ↓
Open in a new tab

Integrative Analysis of the Metabolomics and Proteomics

A total of 12 differential expression metabolites and 27 differential expression proteins that were submitted to Ingenuity Pathway Analysis (IPA) for significantly altered canonical pathways analysis. As shown in Table 3, We found three pathways significantly expressed proteins and metabolites. They were Pyrimidine Metabolism, Metabolic pathways, and Small Molecule Biochemistry. These significantly differential metabolic pathways were selected for more detailed analysis (Figure 7). In these pathways, L-Glutamic acid(L-Glu), Uridine5-monophosphate(UMP), Thymidine 5-monophosphate(dTMP), Uridine, URIDINE-5′-DIPHOSPHATE-MANNOSE(UDP-Gal), CTSH and CTS6 were downregulated, and UMOD, Fxyd2, AHCY, ACY3, Hamp2, CTSE, SCLT1, WFDC2 were upregulated.

TABLE 3.

Significantly altered pathways with differentially expressed proteins and metabolites.

No Pathway name Proteins Metabolites
1 Pyrimidine metabolism Uridine, UMP, dTMP, UDP-Gal
2 Metabolic pathways UMOD,Fxyd2,AHCY,ACY3 L-Glu
3 Small Molecule Biochemistry Hamp2,CTSE,SCLT1,WFDC2 UMP
Open in a new tab

FIGURE 7.

FIGURE 7

Open in a new tab

Network of significantly differential metabolic pathways for Posttraumatic stress disorder. Yellow dashed areas represent the pathways. metabolites are shown as rectangles, and Proteins are shown without no rectangles. Red represents significant upregulation in the PTSD group compared to the control group, green represents significant downregulation.

Discussion

Currently, diagnosis of PTSD is primarily based on subjective symptom representation and patient self-reporting, and the molecular mechanism remains unclear. As such, rates of PTSD in the general population may be significantly underestimated. In the present manuscript, we established a mouse model of PTSD to investigate some of its qualitative biomarkers and potential mechanistic contributors. The elevated cross maze and open-field test were evaluated based on the fact that the plantar shock can continuously produce traumatic stimulation. The mice with the PTSD group were observed to have reduced movement, weakened active exploration ability, and showed negative avoidance and anxiety in comparison to the mice of the control group (Montgomery, 1955; Pellow et al., 1985), indicating significant stress disorder. Combined proteomics and metabolomics analysis was performed revealing 27 significantly dysregulated proteins and 12 significantly dysregulated metabolites.

In this study, urinary uridine levels in the mice model were significantly reduced, suggesting that PTSD can cause metabolic abnormalities of uridine in urine. It has been reported that uridine has a protective effect on mental disorders (Mironova et al., 2018) and can improve neurophysiological functions (Connolly and Duley, 1999). Uridine excretion is mainly achieved through renal and pyrimidine metabolism, producing uracil and β -alanine, which can enter the tricarboxylic acid (TCA) cycle (Gonzalez and Fernandez-Salguero, 1995; Connolly et al., 1996). The homeostasis and metabolic abnormalities of uridine can be accurately monitored by the detection of uridine in urine.

In mammals, in pyrimidine metabolism, uridine (UR) is involved in the de initio synthesis of uridine monophosphate (UMP) to form uridine 5′ -diphosphate (UDP), which can be combined with UDP-galactose and plays an important role in the glycosylation of protein (Connolly and Duley, 1999). It has been reported that pyrimidines are mainly recovered from uridine, which synthesizes RNA and biofilms through pyrimidine nucleotide – lipid conjugates (Yamamoto et al., 2011). In the study, the urine metabolism of uridine (UR), uridine monophosphate (UMP), and UDP-galactose in mice of the PTSD model group showed decreased expression, suggesting that the PTSD mice induced by plantar electric shock exhibit disorder of pyrimidine metabolism.

Glutamate (L-glutamate) is a major excitatory neurotransmitter, and glutamate disorder in the brain is often observed in depression models (Hemanth Kumar et al., 2012; Liu et al., 2016). In this study, the expression of L-glutamate in urine metabolism was decreased in the PTSD model group, while glutamate can provide a nitrogen source for pyrimidine synthesis (Vincenzetti et al., 2016). The pyrimidine metabolism disorder can directly reflect abnormal glutamate metabolism. Studies have reported that patients with PTSD and alcohol use disorder (AUD) have significantly reduced glutamate in the anterior cingulate cortex (ACC; Pennington et al., 2014). Glutamate is the basis of synaptic plasticity and memory formation, and stress response significantly affects glutamate transmission and plays a key role in PTSD (Chambers et al., 1999; Lamprecht and LeDoux, 2004; Popoli et al., 2011; Kelmendi et al., 2016). Urine collects all metabolites of the body and is not regulated by the homeostasis mechanism. Abnormal l-glutamate metabolism detected in urine directly reflects PTSD.

In addition to metabolomic changes, significant proteomics differences were also identified. GO analysis of the urine proteome data showed that proteins with differential expression were mainly located in the extracellular space and extracellular region. It mainly binds to small-molecule, and it is involved in hydrolase activity, endopeptidase activity, and sodium channel regulator activity. Pathway enrichment analysis showed that these proteins are mainly involved in Endocrine and other factor-regulated calcium reabsorption, Lysosome, Renin-angiotensin system, Carbohydrate digestion and absorption, Metabolic pathways, etc.

Hepcidin is a circulating antimicrobial peptide involved in iron homeostasis, inflammation, infection, and metabolic signaling (Lu et al., 2015), There are two murine hepcidin genes: hepcidin-1 (Hamp1) and hepcidin-2 (Hamp2) (Truksa et al., 2007). Studies have shown that in addition to liver level, inflammation can increase the expression level of iron modulin (Kanamori et al., 2017; Silva et al., 2019). In this study, hepcidin-2 (Hamp2) expression increased. It has been reported that people with PTSD show elevated levels of pro-inflammatory cytokines, including IL1B (Dinarello, 2011; Tursich et al., 2014; Passos et al., 2015). In animal studies, IL1B expression level in hippocampus of depressed animal model was increased (Goshen et al., 2008). Therefore, Hamp2 expression may be induced by inflammatory factors in mice with PTSD. At the same time, IPA analysis showed that increased Hamp2 expression was correlated with IL1B, and the relationship between Hamp2 and IL1B in THE urine of PTSD will be further discussed in subsequent studies.

There are some limitations in the present study. First, the abundance of metabolites and proteins in the urine itself is small, and removing the peak degree through database construction ends up in data-loss, suggesting a potential data loss in urine protein-metabolism combined analysis. Second, only 6 eligible mice from each group were used for protein-metabolic analysis, and the results of the discovery omics study were not validated by targeted methods (e.g., western blotting). Therefore, further studies are required to validate these findings.

Conclusion

In this study, based on urine protein-metabolomics combined analysis, we found that the differentially expressed proteins of PTSD in mice were mainly in the extracellular space and region, and showed dysfunction of pyrimidine metabolism. Furthermore, Uridine and L-glutamate can be used as key urine biomarkers to provide a reference for subsequent studies on PTSD.

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics Statement

The animal study was reviewed and approved by the Ethics Committee of Army Medical University.

Author Contributions

DZ, YH, and FL contributed to the design. XW, YWH, WS, and CL participated in the animal experiments. FP, YG, ZZ, and YS assisted to analyze the data. DZ drafted and modified the manuscript. YH and GC provide to financial support. All authors have read and agreed to the manuscript for submission.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Funding

This work was supported by the Foundation of Army Medical University (2018XQN15) and Open Cooperation Program from Key Laboratory of Extreme Environmental Medicine, Ministry of Education of China (PF-KL2020-007).

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnins.2022.828382/full#supplementary-material

Click here for additional data file. (834.4KB, docx)

References

  1. Baloyianni N., Tsangaris G. T. (2009). The audacity of proteomics: a chance to overcome current challenges in schizophrenia research. Expert Rev. Proteomics 6 661–674. 10.1586/epr.09.85 [DOI] [PubMed] [Google Scholar]
  2. Bam M., Yang X., Zhou J., Ginsberg J. P., Leyden Q., Nagarkatti P. S., et al. (2016a). Evidence for epigenetic regulation of pro-inflammatory cytokines, interleukin-12 and interferon gamma, in peripheral blood mononuclear cells from PTSD patients. J. Neuroimmune Pharmacol. 11 168–181. 10.1007/s11481-015-9643-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bam M., Yang X., Zumbrun E. E., Zhong Y., Zhou J., Ginsberg J. P., et al. (2016b). Dysregulated immune system networks in war veterans with PTSD is an outcome of altered miRNA expression and DNA methylation. Sci. Rep. 6:31209. 10.1038/srep31209 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bernstein E., Allis C. D. (2005). RNA meets chromatin. Genes Dev. 19 1635–1655. 10.1101/gad.1324305 [DOI] [PubMed] [Google Scholar]
  5. Bersani F. S., Wolkowitz O. M., Lindqvist D., Yehuda R., Flory J., Bierer L. M., et al. (2016). Global arginine bioavailability, a marker of nitric oxide synthetic capacity, is decreased in PTSD and correlated with symptom severity and markers of inflammation. Brain Behav. Immun. 52 153–160. 10.1016/j.bbi.2015.10.015 [DOI] [PubMed] [Google Scholar]
  6. Bharadwaj R. A., Jaffe A. E., Chen Q., Deep-Soboslay A., Goldman A. L., Mighdoll M. I., et al. (2018). Genetic risk mechanisms of posttraumatic stress disorder in the human brain. J. Neurosci. Res. 96 21–30. 10.1002/jnr.23957 [DOI] [PubMed] [Google Scholar]
  7. Breen M. S., Maihofer A. X., Glatt S. J., Tylee D. S., Chandler S. D., Tsuang M. T., et al. (2015). Gene networks specific for innate immunity define post-traumatic stress disorder. Mol. Psychiatry 20 1538–1545. 10.1038/mp.2015.9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Breslau N., Kessler R. C., Chilcoat H. D., Schultz L. R., Davis G. C., Andreski P. (1998). Trauma and posttraumatic stress disorder in the community: the 1996 Detroit area survey of trauma. Arch. Gen. Psychiatry 55 626–632. 10.1001/archpsyc.55.7.626 [DOI] [PubMed] [Google Scholar]
  9. Bush N. J. (2010). Post-traumatic stress disorder related to cancer: hope, healing, and recovery. Oncol. Nurs. Forum 37 E331–E343. 10.1188/10.ONF.E331-E343 [DOI] [PubMed] [Google Scholar]
  10. Chambers R. A., Bremner J. D., Moghaddam B., Southwick S. M., Charney D. S., Krystal J. H. (1999). Glutamate and post-traumatic stress disorder: toward a psychobiology of dissociation. Semin. Clin. Neuropsychiatry 4 274–281. 10.153/SCNP00400274 [DOI] [PubMed] [Google Scholar]
  11. Connolly G. P., Duley J. A. (1999). Uridine and its nucleotides: biological actions, therapeutic potentials. Trends Pharmacol. Sci. 20 218–225. 10.1016/s0165-6147(99)01298-5 [DOI] [PubMed] [Google Scholar]
  12. Connolly G. P., Simmonds H. A., Duley J. A. (1996). Pyrimidines and CNS regulation. Trends Pharmacol. Sci. 17 106–107. 10.1016/0165-6147(96)20001-x [DOI] [PubMed] [Google Scholar]
  13. Daniels W. M., de Klerk Uys J., van Vuuren P., Stein D. J. (2008). The development of behavioral and endocrine abnormalities in rats after repeated exposure to direct and indirect stress. Neuropsychiatr. Dis. Treat. 4 451–464. 10.2147/ndt.s2450 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. De Bellis M. D., Keshavan M. S., Spencer S., Hall J. (2000). N-acetylaspartate concentration in the anterior cingulate of maltreated children and adolescents with PTSD. Am. J. Psychiatry 157 1175–1177. 10.1176/appi.ajp.157.7.1175 [DOI] [PubMed] [Google Scholar]
  15. de Vries G. J., Mocking R., Lok A., Assies J., Schene A., Olff M. (2016). Fatty acid concentrations in patients with posttraumatic stress disorder compared to healthy controls. J. Affect. Disord. 205 351–359. 10.1016/j.jad.2016.08.021 [DOI] [PubMed] [Google Scholar]
  16. Dinarello C. A. (2011). Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117 3720–3732. 10.1182/blood-2010-07-273417 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Emanuele E., Colombo R., Martinelli V., Brondino N., Marini M., Boso M., et al. (2010). Elevated urine levels of bufotenine in patients with autistic spectrum disorders and schizophrenia. Neuro Endocrinol. Lett. 31 117–121. [PubMed] [Google Scholar]
  18. Gao Y. (2013). Urine-an untapped goldmine for biomarker discovery? Sci. China Life Sci. 56 1145–1146. 10.1007/s11427-013-4574-1 [DOI] [PubMed] [Google Scholar]
  19. Gao Y. (2015). Urine is a better biomarker source than blood especially for kidney diseases. Adv. Exp. Med. Biol. 845 3–12. 10.1007/978-94-017-9523-4_1 [DOI] [PubMed] [Google Scholar]
  20. Girgenti M. J., Duman R. S. (2018). Transcriptome alterations in posttraumatic stress disorder. Biol. Psychiatry 83 840–848. 10.1016/j.biopsych.2017.09.023 [DOI] [PubMed] [Google Scholar]
  21. Goldberg A. D., Allis C. D., Bernstein E. (2007). Epigenetics: a landscape takes shape. Cell 128 635–638. 10.1016/j.cell.2007.02.006 [DOI] [PubMed] [Google Scholar]
  22. Gonzalez F. J., Fernandez-Salguero P. (1995). Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency. Trends Pharmacol. Sci. 16 325–327. 10.1016/s0165-6147(00)89065-3 [DOI] [PubMed] [Google Scholar]
  23. Goshen I., Kreisel T., Ben-Menachem-Zidon O., Licht T., Weidenfeld J., Ben-Hur T., et al. (2008). Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol. Psychiatry 13 717–728. 10.1038/sj.mp.4002055 [DOI] [PubMed] [Google Scholar]
  24. Hemanth Kumar B. S., Mishra S. K., Rana P., Singh S., Khushu S. (2012). Neurodegenerative evidences during early onset of depression in CMS rats as detected by proton magnetic resonance spectroscopy at 7 T. Behav. Brain Res. 232 53–59. 10.1016/j.bbr.2012.03.011 [DOI] [PubMed] [Google Scholar]
  25. Hemmings S. M. J., Malan-Muller S., van den Heuvel L. L., Demmitt B. A., Stanislawski M. A., Smith D. G., et al. (2017). The microbiome in posttraumatic stress disorder and trauma-exposed controls: an exploratory study. Psychosom. Med. 79 936–946. 10.1097/PSY.0000000000000512 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Huang T. L., Lo L. H. (2018). Proteomics approach for biomarker research in major depression: antidepressant effects. Curr. Drug Metab. 19 502–512. 10.2174/1389200219666180404094609 [DOI] [PubMed] [Google Scholar]
  27. Jensen O. N. (2006). Interpreting the protein language using proteomics. Nat. Rev. Mol. Cell Biol. 7 391–403. 10.1038/nrm1939 [DOI] [PubMed] [Google Scholar]
  28. Jing J., Gao Y. (2018). Urine biomarkers in the early stages of diseases: current status and perspective. Discov. Med. 25 57–65. [PubMed] [Google Scholar]
  29. Kaddurah-Daouk R., Krishnan K. R. (2009). Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology 34 173–186. 10.1038/npp.2008.174 [DOI] [PubMed] [Google Scholar]
  30. Kanamori Y., Murakami M., Sugiyama M., Hashimoto O., Matsui T., Funaba M. (2017). Interleukin-1beta (IL-1beta) transcriptionally activates hepcidin by inducing CCAAT enhancer-binding protein delta (C/EBPdelta) expression in hepatocytes. J. Biol. Chem. 292 10275–10287. 10.1074/jbc.M116.770974 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Kangas M., Henry J. L., Bryant R. A. (2005). Predictors of posttraumatic stress disorder following cancer. Health Psychol. 24 579–585. 10.1037/0278-6133.24.6.579 [DOI] [PubMed] [Google Scholar]
  32. Karabatsiakis A., Hamuni G., Wilker S., Kolassa S., Renu D., Kadereit S., et al. (2015). Metabolite profiling in posttraumatic stress disorder. J. Mol. Psychiatry 3:2. 10.1186/s40303-015-0007-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Kelmendi B., Adams T. G., Yarnell S., Southwick S., Abdallah C. G., Krystal J. H. (2016). PTSD: from neurobiology to pharmacological treatments. Eur. J. Psychotraumatol. 7:31858. 10.3402/ejpt.v7.31858 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Kessler R. C., Sonnega A., Bromet E., Hughes M., Nelson C. B. (1995). Posttraumatic stress disorder in the national comorbidity survey. Arch. Gen. Psychiatry 52 1048–1060. 10.1001/archpsyc.1995.03950240066012 [DOI] [PubMed] [Google Scholar]
  35. Lamprecht R., LeDoux J. (2004). Structural plasticity and memory. Nat. Rev. Neurosci. 5 45–54. 10.1038/nrn1301 [DOI] [PubMed] [Google Scholar]
  36. Lauc G., Pezer M., Rudan I., Campbell H. (2016). Mechanisms of disease: the human N-glycome. Biochim. Biophys. Acta 1860 1574–1582. 10.1016/j.bbagen.2015.10.016 [DOI] [PubMed] [Google Scholar]
  37. Li M. (2015). Urine reflection of changes in blood. Adv. Exp. Med. Biol. 845 13–19. 10.1007/978-94-017-9523-4_2 [DOI] [PubMed] [Google Scholar]
  38. Li M., Zhao M., Gao Y. (2014). Changes of proteins induced by anticoagulants can be more sensitively detected in urine than in plasma. Sci. China Life Sci. 57 649–656. 10.1007/s11427-014-4661-y [DOI] [PubMed] [Google Scholar]
  39. Liu L., Zhou X., Zhang Y., Liu Y., Yang L., Pu J., et al. (2016). The identification of metabolic disturbances in the prefrontal cortex of the chronic restraint stress rat model of depression. Behav. Brain Res. 305 148–156. 10.1016/j.bbr.2016.03.005 [DOI] [PubMed] [Google Scholar]
  40. Lu S., Seravalli J., Harrison-Findik D. (2015). Inductively coupled mass spectrometry analysis of biometals in conditional Hamp1 and Hamp1 and Hamp2 transgenic mouse models. Transgenic Res. 24 765–773. 10.1007/s11248-015-9879-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Lundstrom S. L., Yang H., Lyutvinskiy Y., Rutishauser D., Herukka S. K., Soininen H., et al. (2014). Blood plasma IgG Fc glycans are significantly altered in Alzheimer’s disease and progressive mild cognitive impairment. J. Alzheimers Dis. 38 567–579. 10.3233/JAD-131088 [DOI] [PubMed] [Google Scholar]
  42. Mahan A. L., Ressler K. J. (2012). Fear conditioning, synaptic plasticity and the amygdala: implications for posttraumatic stress disorder. Trends Neurosci. 35 24–35. 10.1016/j.tins.2011.06.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Marc D. T., Ailts J. W., Campeau D. C., Bull M. J., Olson K. L. (2011). Neurotransmitters excreted in the urine as biomarkers of nervous system activity: validity and clinical applicability. Neurosci. Biobehav. Rev. 35 635–644. 10.1016/j.neubiorev.2010.07.007 [DOI] [PubMed] [Google Scholar]
  44. Martin C. G., Kim H., Yun S., Livingston W., Fetta J., Mysliwiec V., et al. (2017). Circulating miRNA associated with posttraumatic stress disorder in a cohort of military combat veterans. Psychiatry Res. 251 261–265. 10.1016/j.psychres.2017.01.081 [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Mastrangelo A., Panadero M. I., Perez L. M., Galvez B. G., Garcia A., Barbas C., et al. (2016). New insight on obesity and adipose-derived stem cells using comprehensive metabolomics. Biochem. J. 473 2187–2203. 10.1042/BCJ20160241 [DOI] [PubMed] [Google Scholar]
  46. Mellon S. H., Gautam A., Hammamieh R., Jett M., Wolkowitz O. M. (2018). Metabolism, metabolomics, and inflammation in posttraumatic stress disorder. Biol. Psychiatry 83 866–875. 10.1016/j.biopsych.2018.02.007 [DOI] [PubMed] [Google Scholar]
  47. Mironova G. D., Khrenov M. O., Talanov E. Y., Glushkova O. V., Parfenyuk S. B., Novoselova T. V., et al. (2018). The role of mitochondrial KATP channel in anti-inflammatory effects of uridine in endotoxemic mice. Arch. Biochem. Biophys. 654 70–76. 10.1016/j.abb.2018.07.006 [DOI] [PubMed] [Google Scholar]
  48. Miura Y., Endo T. (2016). Glycomics and glycoproteomics focused on aging and age-related diseases–glycans as a potential biomarker for physiological alterations. Biochim. Biophys. Acta 1860 1608–1614. 10.1016/j.bbagen.2016.01.013 [DOI] [PubMed] [Google Scholar]
  49. Montgomery K. C. (1955). The relation between fear induced by novel stimulation and exploratory behavior. J. Comp. Physiol. Psychol. 48 254–260. 10.1037/h0043788 [DOI] [PubMed] [Google Scholar]
  50. Nedic Erjavec G., Konjevod M., Nikolac Perkovic M., Svob Strac D., Tudor L., Barbas C., et al. (2018). Short overview on metabolomic approach and redox changes in psychiatric disorders. Redox Biol. 14 178–186. 10.1016/j.redox.2017.09.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Nicholas S. B. (2020). Use of urinary proteomics in diagnosis and monitoring of diabetic kidney disease. Lancet Diabetes Endocrinol. 8 261–262. 10.1016/S2213-8587(20)30067-X [DOI] [PubMed] [Google Scholar]
  52. Owens G. P., Baker D. G., Kasckow J., Ciesla J. A., Mohamed S. (2005). Review of assessment and treatment of PTSD among elderly American armed forces veterans. Int. J. Geriatr. Psychiatry 20 1118–1130. 10.1002/gps.1408 [DOI] [PubMed] [Google Scholar]
  53. Pace T. W., Heim C. M. (2011). A short review on the psychoneuroimmunology of posttraumatic stress disorder: from risk factors to medical comorbidities. Brain Behav. Immun. 25 6–13. 10.1016/j.bbi.2010.10.003 [DOI] [PubMed] [Google Scholar]
  54. Park D. I., Stambuk J., Razdorov G., Pucic-Bakovic M., Martins-de-Souza D., Lauc G., et al. (2018). Blood plasma/IgG N-glycome biosignatures associated with major depressive disorder symptom severity and the antidepressant response. Sci. Rep. 8:179. 10.1038/s41598-017-17500-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Passos I. C., Vasconcelos-Moreno M. P., Costa L. G., Kunz M., Brietzke E., Quevedo J., et al. (2015). Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression. Lancet Psychiatry 2 1002–1012. 10.1016/S2215-0366(15)00309-0 [DOI] [PubMed] [Google Scholar]
  56. Pellow S., Chopin P., File S. E., Briley M. (1985). Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 14 149–167. 10.1016/0165-0270(85)90031-7 [DOI] [PubMed] [Google Scholar]
  57. Pennington D. L., Abe C., Batki S. L., Meyerhoff D. J. (2014). A preliminary examination of cortical neurotransmitter levels associated with heavy drinking in posttraumatic stress disorder. Psychiatry Res. 224 281–287. 10.1016/j.pscychresns.2014.09.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Petricoin E. F., Belluco C., Araujo R. P., Liotta L. A. (2006). The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat. Rev. Cancer 6 961–967. 10.1038/nrc2011 [DOI] [PubMed] [Google Scholar]
  59. Popoli M., Yan Z., McEwen B. S., Sanacora G. (2011). The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat. Rev. Neurosci. 13 22–37. 10.1038/nrn3138 [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Rabasa C., Munoz-Abellan C., Daviu N., Nadal R., Armario A. (2011). Repeated exposure to immobilization or two different footshock intensities reveals differential adaptation of the hypothalamic-pituitary-adrenal axis. Physiol. Behav. 103 125–133. 10.1016/j.physbeh.2011.02.022 [DOI] [PubMed] [Google Scholar]
  61. Silva I., Peccerella T., Mueller S., Rausch V. (2019). IL-1 beta-mediated macrophage-hepatocyte crosstalk upregulates hepcidin under physiological low oxygen levels. Redox Biol. 24:101209. 10.1016/j.redox.2019.101209 [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Tanaka M., Li H., Zhang X., Singh J., Dalgard C. L., Wilkerson M., et al. (2019). Region- and time-dependent gene regulation in the amygdala and anterior cingulate cortex of a PTSD-like mouse model. Mol. Brain 12:25. 10.1186/s13041-019-0449-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Tandon R. (2014). Schizophrenia and other psychotic disorders in diagnostic and statistical manual of mental disorders (DSM)-5: clinical implications of revisions from DSM-IV. Indian J. Psychol. Med. 36 223–225. 10.4103/0253-7176.135365 [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Thomson C. A., McColl A., Cavanagh J., Graham G. J. (2014). Peripheral inflammation is associated with remote global gene expression changes in the brain. J. Neuroinflammation 11:73. 10.1186/1742-2094-11-73 [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Truksa J., Lee P., Beutler E. (2007). The role of STAT, AP-1, E-box and TIEG motifs in the regulation of hepcidin by IL-6 and BMP-9: lessons from human HAMP and murine Hamp1 and Hamp2 gene promoters. Blood Cells Mol. Dis. 39 255–262. 10.1016/j.bcmd.2007.06.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Tursich M., Neufeld R. W., Frewen P. A., Harricharan S., Kibler J. L., Rhind S. G., et al. (2014). Association of trauma exposure with proinflammatory activity: a transdiagnostic meta-analysis. Transl. Psychiatry 4:e413. 10.1038/tp.2014.56 [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Van den Berg C. L., Lamberts R. R., Wolterink G., Wiegant V. M., Van Ree J. M. (1998). Emotional and footshock stimuli induce differential long-lasting behavioural effects in rats; involvement of opioids. Brain Res. 799 6–15. 10.1016/s0006-8993(98)00397-7 [DOI] [PubMed] [Google Scholar]
  68. Vanhooren V., Dewaele S., Libert C., Engelborghs S., De Deyn P. P., Toussaint O., et al. (2010). Serum N-glycan profile shift during human ageing. Exp. Gerontol. 45 738–743. 10.1016/j.exger.2010.08.009 [DOI] [PubMed] [Google Scholar]
  69. Vincenzetti S., Polzonetti V., Micozzi D., Pucciarelli S. (2016). Enzymology of pyrimidine metabolism and neurodegeneration. Curr. Med. Chem. 23 1408–1431. 10.2174/0929867323666160411125803 [DOI] [PubMed] [Google Scholar]
  70. Wang Y., Chen J., Chen L., Zheng P., Xu H. B., Lu J., et al. (2014). Urinary peptidomics identifies potential biomarkers for major depressive disorder. Psychiatry Res. 217 25–33. 10.1016/j.psychres.2014.02.029 [DOI] [PubMed] [Google Scholar]
  71. Wilkins M. R., Sanchez J. C., Gooley A. A., Appel R. D., Humphery-Smith I., Hochstrasser D. F., et al. (1996). Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it. Biotechnol. Genet. Eng. Rev. 13 19–50. 10.1080/02648725.1996.10647923 [DOI] [PubMed] [Google Scholar]
  72. Wingo A. P., Almli L. M., Stevens J. S., Klengel T., Uddin M., Li Y., et al. (2015). DICER1 and microRNA regulation in post-traumatic stress disorder with comorbid depression. Nat. Commun. 6:10106. 10.1038/ncomms10106 [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Wu C. H., Chen S. H., Weng L. J., Wu Y. C. (2009). Social relations and PTSD symptoms: a prospective study on earthquake-impacted adolescents in Taiwan. J. Trauma. Stress 22 451–459. 10.1002/jts.20447 [DOI] [PubMed] [Google Scholar]
  74. Wu J., Gao Y. (2015). Physiological conditions can be reflected in human urine proteome and metabolome. Expert Rev. Proteomics 12 623–636. 10.1586/14789450.2015.1094380 [DOI] [PubMed] [Google Scholar]
  75. Yamamoto T., Koyama H., Kurajoh M., Shoji T., Tsutsumi Z., Moriwaki Y. (2011). Biochemistry of uridine in plasma. Clin. Chim. Acta 412 1712–1724. 10.1016/j.cca.2011.06.006 [DOI] [PubMed] [Google Scholar]
  76. Zoldos V., Horvat T., Lauc G. (2013). Glycomics meets genomics, epigenomics and other high throughput omics for system biology studies. Curr. Opin. Chem. Biol. 17 34–40. 10.1016/j.cbpa.2012.12.007 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Click here for additional data file. (834.4KB, docx)

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Articles from Frontiers in Neuroscience are provided here courtesy of Frontiers Media SA

RESOURCES